IPO GMP Today: Hy-Tech Engineers Leads Race Against Symbiotec, Skyways

MUMBAI — Primary market activity intensified on Day 3 of bidding as Hy-Tech Engineers emerged as the frontrunner in overall subscription numbers and unlisted premium gains, outpacing the initial public offerings (IPOs) of pharmaceutical player Symbiotec Pharmalab and logistics major Skyways Air Services. Bourse data and grey market tracking desks showed high retail and non-institutional investor demand across all three issues on Thursday, August 27, 2026. The three-way contest comes during an active week for Indian equity offerings on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).

Comparative Performance on Day 3

Investor interest across the three issues diverged across issue sizes, sector profiles, and valuation metrics.

Hy-Tech Engineers recorded an overall subscription of 51 times, driven by high demand in the Non-Institutional Investor (NII) segment, which stood at 82 times, and the Retail Individual Investor (RII) portion at 64 times.

Symbiotec Pharmalab Limited’s larger ₹1,757-crore issue was subscribed 5.60 times, led by NII bids at 12.84 times and retail participation at 5.35 times.

Skyways Air Services Limited reached an overall subscription of 5.09 times for its ₹582.80-crore offering, with retail investors booking 6.93 times and NIIs at 6.90 times. Qualified Institutional Buyers (QIBs) across all three issues followed typical bidding patterns, reserving their major allocations for the final trading hours.

Grey Market Trends and Listing Estimates

According to grey market tracking desks, Hy-Tech Engineers IPO is commanding an unofficial premium of ₹40 to ₹44 per share over its upper price band of ₹53, pointing to an indicative listing price near ₹93 to ₹97.

Symbiotec Pharmalab traded at a grey market premium (GMP) of ₹340 over its ₹988 upper band, suggesting an estimated opening price of ₹1,328 per share.

Skyways Air Services registered a GMP of ₹38 over its ₹138 upper band, signaling a listing estimate near ₹176 per share.

Why It Matters

The three active public issues provide investors and analysts with a view of liquidity distribution across small-cap engineering, mid-cap logistics, and large-cap active pharmaceutical ingredient (API) manufacturers. High subscription multiples in the engineering vertical point to continued market interest in domestic manufacturing and infrastructure-linked capital expenditure, while asset-light logistics and specialized healthcare maintain baseline institutional attention.

Key Facts at a Glance

• Highest Subscribed: Hy-Tech Engineers led Day 3 demand at 51x total subscription.

• Highest Expected Listing Margin: Hy-Tech Engineers recorded an estimated premium of 75% to 83% over its issue price.

• Largest Issue Size: Symbiotec Pharmalab represents the biggest offering among the three at ₹1,757 crore.

• Listing Timeline: All three companies are scheduled to complete basis of allotment on August 28 and list on BSE and NSE on September 1, 2026.

Official Sources

According to official exchange bidding summaries from the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE):

"Bidding across current active mainboard and SME offerings reflects heavy retail and high-net-worth individual participation heading into the close of subscription windows."

Frequently Asked Questions

Which IPO is winning the race on Day 3?

Hy-Tech Engineers leads the three issues in both total subscription volume (51x) and percentage-based grey market premium (75%–83%).

What is the GMP for Symbiotec Pharmalab today?

Symbiotec Pharmalab’s GMP is quoted at approximately ₹340 per share, indicating a potential listing premium of 34.41% over its issue price of ₹988.

When will these IPO shares list on the exchanges?

Shares of Hy-Tech Engineers, Symbiotec Pharmalab, and Skyways Air Services are tentatively scheduled to list on the NSE and BSE on September 1, 2026.

Sources: National Stock Exchange of India (NSE) | BSE India | Securities and Exchange Board of India (SEBI)